Clinical Trial

Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to find out which way of giving high-dose radiation works best for treatment of cancer that has spread to bone, the spine, soft tissue, or lymph nodes. This study will look at the effects, good and/or bad, of giving 27 Gy in three fractions (3 days) or 24 Gy in one fraction (1 day) using image-guided intensity-modulated radiotherapy (IG-IMRT). IG-IMRT is radiation that is given directly to the cancer site and reduces the exposure to normal tissue. Currently there are no studies that compare the effects of giving radiation in either hypofractionated doses (higher total doses of radiation spread out over several treatment days) or a single-fraction dose (entire radiation dose given in one treatment session). The patient may be asked to participate in an additional part of this study where we will get a a (DW/DCE) MRI before treatment start and within one hour after radiation treatment. If the patient is asked to take part in this portion of the study, all they will need to do is get up to 3 MRIs with standard contrast injection. The purpose of this is to see if as a result of the treatment there are changes in the blood flow going to the cancer which could suggest that the treatment may be successful. In addition some patients can present new lesions and may be asked if they would like to have these new lesions treated on the protocol. If they are given this option, this will not extend their follow up period. The follow up of the new lesions will match with the prior follow up dates.
Protocol Amendment History 39 amendments
This ClinicalTrials.gov record has been amended 39 times since 2010-10-14; most recent amendment 2025-11-03.
Status change: Recruiting → Active, Not Recruiting 2016-05-25
Status change: Suspended → Recruiting 2015-06-10
Status change: Recruiting → Suspended 2015-05-27
Status change: Suspended → Recruiting 2013-10-28
Status change: Recruiting → Suspended 2013-10-09
Trial Details
NCT Number NCT01223248
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: University of Pisa, University of California, San Francisco, The Champalimaud Centre, Lisbon, Portugal
Conditions Melanoma, Ovarian Cancer, Sarcoma, Bone, CNS-Spinal CD/MEMBR, NOS, Lymph Nodes, Soft Tissue
Enrollment 220 participants
Start Date 2010-10
Primary Completion 2026-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2025-11-04